Gary Ulaner, MD, PhD and Jeremy Force, DO review estrogen receptor (ER)-positive breast cancer and the various strategies available for diagnosing estrogen receptor (ER)-positive breast cancer.
Back
Optimizing Imaging in ER-positive Metastatic Breast Cancer to Improve Clinical Outcomes
Gary Ulaner, MD, PhD and Jeremy Force, DO discuss the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18F-FES-PET imaging in diagnosis and treatment of ER-positive breast cancer and in improving patient outcomes.
Optimizing Imaging in ER-positive Metastatic Breast Cancer to Improve Clinical Outcomes
Episodes
All
All
Experts provide an overview of the imaging modalities that can detect estrogen receptor status in patients with breast cancer.
Dr Gary Ulaner compares the role of FDG-PET and FES-PET imaging in ER+ Breast Cancer and the ability of each of the 2 techniques in assessing ER status.
Expert perspective on the applications of FES-PET imaging in treatment decision-making in patients with breast cancer.
A comprehensive analysis of the potential role of FES-PET imaging in assessing ER status in tumors that are difficult to biopsy and in evaluating the extent of disease.
Dr Jeremy Force illustrates how FES-PET aids in the care of patients with breast cancer through a clinical case.
Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.
Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.
Dr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer
2
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
3
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
MOMENTUM Trial Aims to Add Further Evidence for Cemsidomide in R/R Myeloma
5